Influence of formulation factors on PpIX production and photodynamic action of novel ALA-loaded microparticles

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 2, 2009, Pages 55-70

  Donnelly, Ryan F ^a   McCarron, Paul A ^b   Al Kassas, Rasil ^a   Juzeniene, Asta ^c   Juzenas, Petras ^c   Iani, Vladimir ^c   Woolfson, A David ^a   Moan, Johan ^c,d  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

5 aminolevulinic acid; Microparticles; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; PROPYLENE GLYCOL; PROTOPORPHYRIN; MICROSPHERE; PHOTOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; FEMALE; FLUORESCENCE; IMAGING SYSTEM; LASER; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; SKIN; SOLID TUMOR; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; EXPERIMENTAL NEOPLASM; GEL; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; NUDE MOUSE; PATHOLOGY; PHOTOCHEMOTHERAPY; SKIN TUMOR;

ADMINISTRATION, CUTANEOUS; AMINOLEVULINIC ACID; ANIMALS; FEMALE; GELS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSPHERES; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROPYLENE GLYCOL; PROTOPORPHYRINS; SKIN NEOPLASMS;

EID: 63049095402     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.645     Document Type: Article

References (42)

1. Daniell MD, Hill JS. A history of photodynamic therapy. Aust NZ J Surg 1991; 61: 340-348.
2. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J Photochem Photobiol B: Biol 1990; 6: 143-148.
3. Cairnduff F, Stringer MR, Hudson EJ, et al. Superficial photodynamic therapy with topical 5-aminolevulinic acid for superficial primary and secondary cancer. Br J Cancer 1994; 69: 605-608.
4. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical 5-aminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B: Biol 1995; 29: 53-57.
5. Soler AM, Warloe T, Tausjo J, Berner A. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: A one-year follow-up study. Acta Dermatol Venereol 1999; 79: 204-206.
6. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical 5-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-751.
7. Morton CA, Whitehurst C, Moseley H, et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996; 135: 766-771.
8. Morton CA, Whitehurst C, Moore JV, et al. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000; 143: 767-772.
9. Meijnders PJN, Star WM, De Bruijn RS, et al. Clinical results of photodynamic therapy for superficial skin malignancies or actinic keratosis using topical 5-aminolevulinic acid. Lasers Med Sci 1996; 11: 123-131.
10. Jeffes EW, McCullough JL, Weinstein GP, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: A pilot dose-ranging study. Arch Dermatol 1997; 133: 727-732.
11. Dijkstra AT, Majoie IML, van Dongen JWF, et al. Photodynamic therapy with violet light and topical 5-aminolevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol 2001; 15: 550-554.
12. Morton CA, MacKie RM, Whitehurst C, et al. Photodynamic therapy for basal cell carcinoma: Effect of tumour thickness and duration of photosensitiser application on response. Arch Dermatol 1998; 134: 248-249.
13. Soler AM, Warloe T, Berner A, et al. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolevulinate-based photodynamic therapy alone with prior curettage. Br J Dermatol 2001; 145: 467-471.
14. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem Photobiol 2005; 81: 750-767.
15. Morrow DIJ, Garland MJ, McCarron PA, et al. Innovative drug delivery strategies for topical photodynamic therapy using porphyrin precursors. J Environ Pathol Toxicol Oncol 2007; 26: 105-116.
16. McCarron PA, Donnelly RF, Zawislak A, et al. Design and evaluation of a water-soluble bioadhesive patch formulation for cutaneous delivery of 5-aminolevulinic acid to superficial neoplastic lesions. Eur J Pharm Sci 2006; 27: 268-279.
17. Donnelly RF, McCarron PA, Ma LW, et al. Facilitated delivery of ALA to inaccessible regions via bioadhesive patch systems. J Environ Pathol Toxicol Oncol 2006; 25: 1-14.
18. Donnelly RF, Ma LW, Juzenas P, et al. Topical bioadhesive patch systems enhance selectivity of protoporphyrin IX accumulation in tumours. Photochem Photobiol 2006; 82: 670-675.
19. McCarron PA, Donnelly RF, Andrews GP, et al. Stability of 5-aminolevulinic acid in novel non-aqueous gel and patch-type systems intended for topical application. J Pharm Sci 2005; 94: 1756-1771.
20. McLoone N, Donnelly RF, McCarron PA, et al. Aminolevulinic acid penetration into nodular basal cell carcinomas: Influence of different concentrations and application times on amounts of ALA delivered via a bioadhesive patch. Clin Photodyn 2004; 1: 5-6.
21. McCarron PA, Donnelly RF, Woolfson AD. Autoradiographic and scintillation analysis of 5-aminolevulinic acid permeation through epithelialized tissue: implications for topical photodynamic therapy of superficial gynaecological neoplasias. Pharm Res 2008; 25: 812-826.
22. McCarron PA, Donnelly RF, Al-Kassas R. Microencapsulation of water-soluble drugs in low melting temperature triglycerides using a spray congealing procedure. J Microencaps 2008; 25: 365-378.
23. Al-Kassas R, Donnelly RF, McCarron PA. Characterisation, stability and drug release of aminolevulinic acid-loaded Witepsol microparticles manufactured using a spray congealing procedure: implications for topical photodynamic therapy. J Pharm Pharmacol 2008; submitted.
24. Juzeniene A, Juzenas P, Ma LW, et al. Topical application of 5-aminolaevulinic acid, methyl 5-aminolaevulinate and hexyl 5-aminolaevulinate on normal human skin. Br J Dermatol 2006; 155: 791-799.
25. Juzenas P, Juzeniene A, Stakland S, et al. Photosensitizing effect of protoporphyrin IX in pigmented melanoma of mice. Biochem Biophys Res Commun 2002; 297: 468-472.
26. Kostenich G, Orenstein A, Roitman L, et al. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system. J Photochem Photobiol B: Biol 1997; 39: 36-42.
27. Casas A, Fukuda H, Meiss R, et al. Topical and intratumoral photodynamic therapy with 5-aminolevulinic acid in a subcutaneous murine mammary adenocarcinoma. Cancer Lett 1999; 141: 29-38.
28. Gilmore BF, McCarron PA, Morrow DIJ, et al. In vitro phototoxicity of 5-aminolevulinic acid and its methyl ester and the influence of barrier properties on their release from a bioadhesive patch. Eur J Pharm Biopharm 2006; 63: 295-309.
29. Krems I, Spoerri PE. The pyrazines. Chem Rev 1947; 40: 290-358.
30. Gadmar OB, Moan J, Scheie E, et al. The stability of 5-aminolevulinic acid in solution. J Photochem Photobiol B: Biol 2002; 67: 187-193.
31. Bunke A, Zerbe O, Schmid H, et al. Degradation mechanism and stability of 5-aminolevulinic acid. J Pharm Sci 2000; 89: 1335-1341.
32. Bunke A, Schmid H, Burmeister G, et al. Validation of a capillary electrophoresis method for determination of 5-aminolevulinic acid and degradation products. J Chrom A 2000; 883: 285-290.
33. Novo M, Huttmann G, Diddens H. Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. J Photochem Photobiol B: Biol 1996; 34: 143-148.
34. Elfsson B, Wallin I, Eksborg S, et al. Stability of 5-aminolevulinic acid in aqueous solution. Eur J Pharm Sci 1998; 7: 87-91.
35. Casas A, Fukuda H, Di Venosa G, et al. The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolevulinic acid. Implications in cutaneous photodynamic sensitisation. Br J Dermatol 2000; 143: 564-572.
36. Pierre MBR, Tedesco AC, Marchetti JM, et al. Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: Preparation and in vitro permeation study. BMC Dermatol 2001; 1: 1471-1476.
37. Hurlimann AF, Hanggi G, Panizzon RG. Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 1998; 197: 248-254.
38. McCarron PA, Woolfson AD, Donnelly RF, et al. Influence of plasticiser type and storage conditions on the properties of poly(methyl vinyl ethercomaleic anhydride) bioadhesive films. J Appl Polym Sci 2004; 91: 1576-1589.
39. http://www.engineeringtoolbox.com/specificheatfluids-d_151.html. Accessed 10 July 2007.
40. Sznitowska M, Janicki S, Gos T. The effect of sorption promoters on percutaneous permeation of a model zwitterion baclofen. Int J Pharm 1996; 137: 125-132.
41. Yamashita F, Koyama Y, Kitano M, et al. Analysis of in vivo skin penetration enhancement by oleic acid based on a two-layer diffusion model with polar and nonpolar routes in the stratum corneum. Int J Pharm 1995; 117: 173-179.
42. Moan J, Van den Akker JTHM, Juzenas P, et al. On the basis for tumor selective in the 5-aminolevulinic acid-induced synthesis of protoporphyrin IX. Int J Cancer 2001; 92: 139-143.